BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berry CM. Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies? Hum Vaccin Immunother 2018;14:796-9. [PMID: 28854120 DOI: 10.1080/21645515.2017.1363135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Samad N, Sodunke TE, Banna HA, Sapkota A, Fatema AN, Iskandar K, Jahan D, Hardcastle TC, Nusrat T, Chowdhury TS, Haque M. Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic. Risk Manag Healthc Policy 2020;13:2707-28. [PMID: 33262668 DOI: 10.2147/RMHP.S281388] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Del Rosario JMM, Smith M, Zaki K, Risley P, Temperton N, Engelhardt OG, Collins M, Takeuchi Y, Hufton SE. Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity. Front Immunol 2020;11:627. [PMID: 32547534 DOI: 10.3389/fimmu.2020.00627] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
3 Foerster J, Molęda A. Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis. Viruses 2020;12:E438. [PMID: 32294982 DOI: 10.3390/v12040438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Esposito S. 100 years since the 1918 influenza pandemic. Hum Vaccin Immunother 2018;14:504-7. [PMID: 29553916 DOI: 10.1080/21645515.2018.1446591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Jester B, Uyeki T, Jernigan D. Readiness for Responding to a Severe Pandemic 100 Years After 1918. Am J Epidemiol 2018;187:2596-602. [PMID: 30102376 DOI: 10.1093/aje/kwy165] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
6 Abbas AT, El-Kafrawy SA, Sohrab SS, Azhar EIA. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections.Hum Vaccin Immunother. 2019;15:264-275. [PMID: 30230944 DOI: 10.1080/21645515.2018.1514224] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
7 Sun Z, Yan L, Tang J, Qian Q, Lenberg J, Zhu D, Liu W, Wu K, Wang Y, Lu S. Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. Virus Res 2018;243:75-82. [PMID: 29051051 DOI: 10.1016/j.virusres.2017.10.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]